MAM
RVMD icon

Martingale Asset Management’s Revolution Medicines RVMD Stock Holding History

Martingale Asset Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,000
Closed -$205K – 877
2022
Q1 		$205K Hold
8,000
– – ﹤0.01% 783
2021
Q4 		$202K Hold
8,000
– – ﹤0.01% 797
2021
Q3 		$221K Hold
8,000
– – ﹤0.01% 805
2021
Q2 		$254K Buy
+8,000
New +$279K ﹤0.01% 753

Other funds holding RVMD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Martingale Asset Management's RVMD Position: Q2 2022 in Review

Martingale Asset Management sold out of Revolution Medicines (RVMD) in Q2 2022, closing a stake of 8,000 shares — an estimated $205K sold.

Martingale Asset Management first reported a position in RVMD in Q2 2021 and held it in 4 quarters. The position peaked at $254K in Q2 2021. 135 funds tracked by Wall St. Rank hold RVMD as of Q2 2022.

  • Martingale Asset Management reported no remaining Revolution Medicines position as of Q2 2022 after selling out during the quarter.
  • Martingale Asset Management sold 8,000 Revolution Medicines shares in Q2 2022, an estimated $205K.
  • Martingale Asset Management first reported a position in Revolution Medicines in Q2 2021 and held it in 4 quarters.
  • Martingale Asset Management's Revolution Medicines position peaked at $254K in Q2 2021.
  • 135 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2022.

Based on Martingale Asset Management's 13F filing for Q2 2022, filed 11 Aug 2022.